



ScienceDirect

Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/jval

Themed Section: Curative Therapies

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy



Michael F. Drummond, MCom, DPhil,^{1,*} Peter J. Neumann, ScD,² Sean D. Sullivan, PhD,³ Frank-Ulrich Fricke, PhD,⁴ Sean Tunis, MD, MSc,⁵ Omar Dabbous, MD, MPH,⁶ Mondher Toumi, PhD⁷

¹Centre for Health Economics, University of York, York, England, UK; ²Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA; ³CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; ⁴Fakultät Betriebswirtschaft, Technische Hochschule Nürnberg Georg Simon Ohm, Nürnberg, Germany; ⁵Center for Medical Technology Policy, Baltimore, MD, USA; ⁶AveXis Inc, Bannockburn, IL, USA; ⁷Public Health Department, Aix-Marseille University, Marseille, France.

ABSTRACT

The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of healthcare interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodological reference case is required. The aim of this article was to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.

Keywords: cost-effectiveness analysis, drug pricing, reimbursement, specialty drugs

VALUE HEALTH. 2019; 22(6):661–668

Introduction

The concept of a “reference case,” first proposed by the US Panel on Cost-Effectiveness in Health and Medicine,¹ has been used to specify the required methodological features of economic evaluations of healthcare interventions in different jurisdictions.^{2,3} In the United States, the Institute for Clinical and Economic Review has recently produced a reference case that is based, in part, on the Second US Panel.⁴ The rationale for the reference case is to improve the quality and comparability of cost-effectiveness analyses through the incorporation of standard methodological practices. Nevertheless, as others have noted, the same economic evaluation methods may not be equally applicable to every type of medical intervention. This argument has been made in the case of medical devices, owing to the existence of the “learning curve” and rapid, incremental innovation,⁵ and interventions for rare diseases, because of the difficulties in conducting controlled clinical studies and the potential existence of unique aspects of “social value.”⁶ Often the argument is not for a completely different reference case, but rather for particular attention to be paid to a number of specific characteristics of the health technologies and patient population concerned.

Gene therapy is a novel approach that uses specific genetic material to treat or prevent disease. The technologies used may

allow physicians to treat a disorder by inserting a gene into patients' cells instead of using drugs or surgery. Several approaches to gene therapy are being evaluated, including (1) replacing a mutated gene that causes disease with a healthy copy of the gene, (2) inactivating, or “knocking out,” a mutated gene that is functioning improperly, and (3) introducing a new gene into the body to help fight a disease. Although representing a major breakthrough in therapy, in particular for those diseases that currently have no effective therapy, gene therapies are likely to be very expensive.

In the case of gene therapy, there is a difference of opinion on whether a specific methodological reference case is required. Hepple et al⁷ argue that the general National Institute for Health and Care Excellence (NICE) reference case can be applied in the example of chimeric antigen receptor T-cell therapy. Marsden et al⁸ question this argument and suggest that patients with rare genetic diseases, along with the gene replacement therapies they use, present a unique set of conditions that warrant equally unique analytic approaches to estimating value for money. Furthermore, Jönsson et al⁹ suggest that in the case of advanced therapy medicinal products, which include gene therapy approaches, 3 issues pose challenges for current methods: the uncertainty about future costs and benefits, aspects of value that are not captured in the quality-adjusted life-year (QALY), and the

* Address correspondence to: Michael F. Drummond, MCom, DPhil, Centre for Health Economics, Alcuin A Block, University of York, Heslington, York YO10 5DD, England, UK. Email: mike.drummond@york.ac.uk

1098-3015/\$36.00 - see front matter Copyright © 2019, ISPOR—The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. <https://doi.org/10.1016/j.jval.2019.03.012>

social and ethical aspects of the implications of discounting. Finally, Garrison et al¹⁰ argue that the novel aspects of value provided by gene therapies justify a higher (cost-effectiveness) decision-making threshold.

The aim of this article was to undertake a more detailed analysis of the particular characteristics of gene therapy and the extent to which these suggest modifications to the methods used in economic evaluation and the applicability of the general reference case. The key methodological features of economic evaluations are discussed in turn. For this article we focus on the most severe diseases with therapies that have the potential to produce large, sustained benefits.

Key Methodology Issues

Genetic diseases are highly variable in terms of the age of patients at first clinical presentation, symptoms, morbidity, and life expectancy. Gene therapies have a number of particular characteristics. They have the potential to deliver benefits that range from “potentially curative” treatments of rare, disabling, and/or life-threatening conditions often targeting young children to more moderate benefits for less severe conditions. Taken individually, none of these characteristics is exclusive to gene therapy. There are several therapies, of all types, that treat severe, disabling, or life-threatening conditions. There are many other treatments for rare diseases or diseases that affect children. Rather it is the *confluence* of these various characteristics in the case of gene therapy that leads to specific methodological challenges and possibly the need for a different reference case. A number of these challenges are described herein.

Assessment of Clinical Effectiveness and Safety

There are a number of characteristics of gene therapy that lead to challenges in the assessment of clinical effectiveness and safety. First, because some new therapies, including gene therapy, may bring sizable benefits in high unmet-need areas, or life-shortening conditions, policy makers have implemented a number of regulatory pathways to accelerate marketing authorization. These include accelerated approval breakthrough therapy designation and priority review,¹¹ or early dialogue, accelerated assessment, and adaptive pathways.^{12,13}

These pathways potentially allow rapid patient access to new innovative therapies, but generally result in regulatory approval with limited clinical data. The large anticipated benefits may outweigh the risks, allowing regulators to grant marketing authorization, whereas the actual magnitude of this benefit remains uncertain at the time of approval. In the field of cancer this has already proven to be problematic. Kim and Prasad¹⁴ considered 36 cancer drugs, many that had been given accelerated approval by the Food and Drug Administration on the basis of a surrogate endpoint (rate or response or progression-free survival). On the basis of a median follow-up of 4.4 years, only 5 of the drugs had by that time demonstrated improvement in overall survival in randomized controlled trials, 18 had failed to show any improvement, and 11 had no results.

This raises considerable uncertainty when health technology assessment (HTA) agencies or payers attempt to understand the value of such therapies. The primary endpoint is often a surrogate, raising questions about the validity and predictability of such endpoints, especially in rare, poorly studied conditions. The short-term evidence requires extrapolation to long-term benefit often with little insight on the most appropriate model, leading to high uncertainty in long-term outcome. And because of the relatively high costs of these new classes of treatment, payers, be they

governments or private insurers, may be reluctant to support coverage when the long-term benefit is uncertain.

Second, gene therapies often target rare, but serious, conditions. This raises a number of challenges in the conduct of conventional randomized controlled trials. Given the small patient population, recruitment of sufficient patients for adequate enrollment in a trial is often difficult. In addition, patients or their caregivers may be reluctant to enter in a placebo-controlled trial for a very severe life-shortening condition when an experimental therapy exists with the potential to offer a cure. Therefore, clinical studies, even if randomized, may be small and there remains a preponderance of single-arm uncontrolled studies.

A recent review of gene therapy studies reported that 47.2% of gene therapy clinical trials enrolled fewer than 20 patients and that the median size of the trial populations was 213 patients.¹⁵ Because gene therapies often target rare conditions, to increase the size of the trial population, researchers have to sacrifice its homogeneity by including participants with different baseline characteristics or from a range of settings. The review also stated that 20% of the identified trials included both children and adults. Other factors, including the development of these therapies in a limited number of highly specialized centers and the heterogeneity of the patient population, raise questions about the transferability and generalizability of the results of clinical studies.

Because of the large benefit expected from such therapies and the lack of effective comparators, manufacturers often gravitate to single-arm small trials in 1 single center or very few highly specialized centers. Nevertheless, there are differences of opinion on the usefulness of these studies and the validity of historical controls. Historical cohorts may be acceptable when the population is relatively homogeneous, when confounding factors affecting outcomes are well known, when patient management is well established and standardized, when the primary endpoint is objective and robust, and when the effect size of the new therapy is substantial versus the historical cohort. In this case, a matched propensity scoring method may be helpful to appreciate the effect size of the benefit.

As mentioned, these challenges are not unique to gene therapy, but they are particularly concentrated and often with a large magnitude in these treatments. Therefore, in designing the clinical development program for these therapies, more attention needs to be paid to:

- minimizing the biases in observational studies used to establish a reliable historical cohort;
- studying heterogeneity in the patient population;
- understanding the confounding factors affecting the study outcome;
- using appropriate statistical methodology for historical comparisons;
- considering the generalizability of the clinical data;
- validating surrogate endpoints; and
- using appropriate extrapolation methods to estimate long-term benefit.

A detailed discussion of the methodological solutions to these issues is beyond the scope of this article, but any reference case for the evaluation of gene therapy would need to pay particular attention to the following points.

Small or single-arm trials

When trials are small, or consist of only one treatment arm, decision makers are likely to question the validity of the clinical evidence. Therefore, it is necessary to find data from outside the trial to provide sufficient evidence of treatment effect. One

approach is to find, or assemble, a historical cohort of patients treated before the advent of the new therapy, which can be used as a comparator, or to supplement the trial evidence. An example is the single-arm, multicenter clinical development program for the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel for patients with relapsed or refractory large B-cell lymphoma. To assess comparative effectiveness and safety, patients in the active therapy arm were compared with a historical control group constructed from observational data.¹⁶ The evaluation by the Institute for Clinical and Economic Review and a subsequent cost-effectiveness analysis also used the historical control group to derive estimates of incremental benefit.¹⁷

The main challenge is that most of the methodological approaches for matching or making indirect comparisons require data on patient characteristics that can be used as covariates in a statistical analysis. These data can be collected on the trial population, provided this need is anticipated in the design of the clinical trial. Finding equivalent data on a historical cohort can be more challenging, especially when relying on existing data sources.

An International Society for Pharmacoeconomics and Outcomes Research (ISPOR) task force¹⁸ developed a questionnaire to assess the relevance and credibility of observational studies, the “relevance” section of which is helpful in judging the suitability of existing data sets. Nevertheless, a preferable approach would be for manufacturers to anticipate the likely need for a historical cohort in advance. This would enable the consideration of factors such as (1) ensuring that the patients in the cohort are equivalent to those expected to be enrolled in the trial, (2) collecting the data on patient characteristics for use as covariates, and (3) ensuring that the measurement outcomes are equivalent to those planned for the trial.

Surrogate outcomes

The issues in the use of surrogate outcomes in clinical trials have been widely discussed.¹⁹ Sometimes the use of a surrogate outcome is unavoidable, but it is important to know whether any attempts have been made to evaluate and validate it. Several approaches to the validation of surrogates exist and are reviewed in a study by Ciani et al.²⁰ Validation can be considered as a 3-level hierarchy: (1) biological plausibility, (2) the association between the surrogate and the final outcome across cohorts or at the level of the individual patient, and (3) evidence that the technology improves the surrogate and the final outcome in several clinical trials. The third level of evidence is unlikely to be available in the case of gene therapies for rare diseases, but the same surrogate may have been evaluated in similar diseases affecting a larger patient population.

Nevertheless, even if all these issues were successfully tackled, it is unlikely that all the uncertainties concerning clinical effectiveness and safety will be reduced to a level typically accepted by payers, or those conducting HTAs. Furthermore, as in all new therapies, there may be substantial adverse consequences of treatment that are currently unknown, a concern heightened with truly novel approaches such as gene therapies. There is also uncertainty over the durability of treatment and, in the case of single-dose therapy, whether an additional dose would be required at a later stage. Therefore, it is likely that a prerequisite from payers for reimbursement of gene therapies would be ongoing monitoring of the patient’s condition, perhaps linked to a performance-based risk-sharing arrangement.²¹ We return to this issue later, in the context of dealing with uncertainty in economic evaluations.

Study Perspective

In many jurisdictions, the study perspective for cost-effectiveness analyses is specified by the relevant decision maker or budget holder. For example, NICE in England and Wales specifies a National Health Service and personal social services perspective in its cost-effectiveness analyses.³ In other jurisdictions (eg, Sweden), authorities prefer a societal perspective, accounting for all costs and benefits regardless of where they fall.²²


The Second Panel on Cost-Effectiveness in Health and Medicine recommended that, for purposes of comparability, relevance, and completeness, analysts conducting cost-effectiveness analyses should include 2 reference cases—one based on a societal perspective and the other on a healthcare sector perspective.⁴ As Neumann et al⁴ noted, “The former is recommended because of the importance of capturing the broad consequences of health interventions, including those outside the health care sector; the latter is a nod to pragmatism, because it is more closely tied to the resource implications considered by health sector decision makers.” The Second Panel emphasized, however, that where specific decision makers have been identified, such as a particular public or private payer, analysts may wish to present results from this decision maker’s perspective in addition to the Reference Case perspectives. The panel further recommended inclusion of an “impact inventory,” a structured table listing the health and non-health-related effects of an intervention that should be considered in a societal reference case analysis.⁴

The issue of perspective is critical for technologies such as gene therapies, for which there is the prospect of long-term benefits, allowing the patient to live a relatively normal life. In particular, related and nonrelated healthcare costs would need to be considered. If gene therapy does lead to a complete resolution of the patient’s health problem, it may result in a substantial reduction in related healthcare costs, although there may be a possible increase in nonrelated healthcare costs. Inclusion of nonrelated healthcare costs and consequences, such as impacts on caregivers and social services and on economic productivity, can have profound effects on whether a therapy is deemed cost-effective at a given price. When therapy is for children, these effects (including impacts on educational achievement and subsequent consequences for educational costs, productivity, and health outcomes) can be substantial. Under a societal perspective, all these current and future nonrelated healthcare costs and consequences would need to be considered in the cost-effectiveness analysis. Conducting a cost-effectiveness analysis of gene therapies from both a societal and a healthcare sector perspective, as recommended by the Second Panel, can highlight for decision makers the difference it makes when broader consequences are considered.

Valuation of Benefits

The concept of “value” in assessing health technologies remains one of the most debated subjects in the field. Value assessments traditionally include a definition of benefits, often limited to the gains in length and quality of life (and often expressed as QALYs), cost savings, and productivity gains incurred by the patient or caregivers returning to work. Nevertheless, a need for a broader definition of value continues to be debated. The ISPOR Special Task Force on US Value Assessment Frameworks²³ recently described various “novel” elements of value worthy of consideration, many of which have relevance for gene therapies²⁴ (see Figure 1).

Figure 1. Potential elements of value to consider in economic evaluations.



Note. Green circles: core elements of value; light blue circles: common but inconsistently used elements of value; dark blue circles: potential novel elements of value; blue line: value element included in traditional payer or health plan perspective; and red line: value element also included in societal perspective. Source: Lakdawalla et al.²⁴

Severity of disease

In the standard application of QALYs, each QALY gained is considered to be of the same value, no matter who receives it. Many of the diseases treated by gene therapy are, however, severe or life-threatening. Severity of disease has been discussed as a potential element of value that is not adequately considered in standard cost-effectiveness estimates.²⁵ In terms of QALYs, this implies that a gain in quality of life from, say, 0.3 to 0.5 on the scale is worth more than a gain from 0.5 to 0.7.²⁶ It has also been suggested that treatments for individuals near end of life (or proximity to death) may be more valuable, either because the individuals themselves place higher value on the health gain or because they and others feel that society should give priority to treating individuals with severe diseases.²⁷ A recent study links these 2 concepts by arguing that a consideration in providing treatment should be the “proportional QALY shortfall” that individuals face, namely, the difference between the remaining QALYs they are likely to experience with their current disease, as compared with a healthy person of their age.²⁸

In interpreting the literature on this topic and its relevance to gene therapies, a key question is whether individuals are responding on the basis of views about care for themselves or on what they feel society should do for others. Most of the studies focus on the second issue, although sometimes there are doubts about the basis on which respondents have answered the questions.²⁸ Nevertheless, a recent study by Taylor et al²⁹ suggests that individuals place a greater weight (for themselves) on improvements in health from more severe health states than on equivalent improvements from less severe states. Therefore, therapies that improve the health of individuals in severe states may be considered to be of higher value. Some of the gene therapies that have been developed so far are for serious diseases, such as retinal blindness and spinal muscular atrophy, but it is too early to conclude that this trend will be maintained as more gene therapies are developed.

Value to caregivers

The severity of many of the diseases treated by gene therapy means that the burden falling on caregivers is likely high. The burden has 2 components: the emotional stress of seeing a close relative or friend suffering from a serious disease and the time spent in providing informal care. The emotional component may

be particularly high in the case of caring for a sick child. A number of estimates of caregiver burden exist in the literature, mainly focusing on the value of the time spent in caring,³⁰ although some methods estimate the broader impact on caregiver well-being.³¹ Although the burden on caregivers is widely recognized, it is infrequently measured in economic evaluations.³²

Insurance value

Insurance value relates to the benefit individuals derive from knowing that they are protected—physically (by having access to treatment if they require it) and financially (in case they have to incur the cost of treatment). Although the insurance value can be applied to any health technology, Jena and Lakdawalla⁶ argue that insurance value is disproportionately high in the case of rare, serious diseases, because they pose greater risk to healthy consumers, given that they involve bigger reductions in well-being in the event of illness to themselves or a loved one. Also, unlike the conventional measures of the value of therapy, insurance value applies to all consumers, not just those who suffer from the relevant disease.

Scientific spillovers

Scientific spillovers refer to the knowledge created in the development of products that have broad benefits for society as the information becomes a “public good” and is used in the discovery of other therapies. That is, when a drug with a new mechanism of action is discovered, it may facilitate the development of other therapies that will deliver benefits to future patients. Given that gene therapy is in the early stages of development, it is possible that other discoveries will follow, but the extent of it is unknown at this point. Scientific spillovers have been documented using National Institutes of Health funding as the “intervention” and clinical trial starts as the “outcome.”³³ Nevertheless, the value of innovation is notoriously hard to assess and there is debate about whether it is best funded through higher product prices or other methods and whether, in giving a price premium for the innovation, payers risk paying twice if the developers of the subsequent therapies also require a reward for the innovation they represent.

Incorporating broader elements of value into decision making

Ideally, the various aforementioned elements of value would need to be measured and then combined with the conventional benefits (eg, QALYs) to give an overall assessment of the value of gene therapy. Lakdawalla et al²⁴ offer some suggestions for how these measurements could be made, many of which are based on willingness-to-pay approaches. Nevertheless, in another report of the ISPOR Special Task Force, Phelps et al³⁴ point to some of the difficulties in aggregation. They argue that monetary valuation within a cost-benefit analysis framework raises concerns of equity and fairness. The main alternative approach to aggregation, multicriteria decision analysis, shows promise but has had limited application in real-life decision-making settings and more research is needed on key aspects of multicriteria decision analysis modeling.

In practice, payers and those undertaking HTAs either use “deliberative decision making” to incorporate these novel elements of value or modify their decision rule (eg, raise their cost-effectiveness threshold) to accommodate them.³⁵ One of the criticisms of deliberative decision making, where decision makers consider elements of value that are not included in the estimate of the incremental cost-effectiveness ratio, is that these discussions are often unstructured and lacking in transparency. In Scotland, the Scottish Medicines Consortium³⁶ has a more structured

approach that defines a series of “modifiers” to their decision-making threshold that include factors such as the severity of disease, evidence of a substantial improvement in life expectancy, absence of other therapeutic options of proven value, and bridging to another proven therapy.

In Sweden, although there is no official cost per QALY threshold, the Dental and Pharmaceutical Benefits Board (TLV) makes adjustments in its decisions to account for severity of disease.³⁷ More recently, in an example particularly relevant to gene therapy, NICE in England has stated that it will consider a cost-effectiveness threshold of up to £100 000/QALY, in its Highly Specialized Treatments Programme, in situations where the new therapy gives a gain of more than 10 QALYs to patients over their lifetime, rising to £300 000/QALY if the therapy gives a gain of 30 QALYs.³⁸ This is considerably higher than the threshold of £20 000/QALY in the institute’s “standard” Technology Appraisal Programme.

From the perspective of gene therapy, it would be important to have the potential to identify the aforementioned elements of value. Then it would be for decision makers to decide whether to consider them in their decision-making processes.

Time horizon and discount rates

The general recommendation for the choice of time horizon in economic evaluations is that it should be long enough to capture all the relevant costs and benefits of the treatment being evaluated.^{4,39} Gene therapies used in severe or life-threatening conditions have the potential to extend individuals’ life expectancy considerably, which suggests projecting the predicted costs and outcomes over a long period of time, probably a person’s lifetime. Therefore, it would make sense to present the analysis using different time horizons in a series of scenario analyses, with the different time horizons relating to different levels of knowledge about treatment effect. For example, depending on the length of follow-up in existing clinical studies, there may be good data on life expectancy over 5 years, but limited data over 10 or 15 years.

Most reference cases for economic evaluation recommend or require that the same discount rate should be applied to both costs and benefits. Jönsson et al⁹ question this in the case of advanced therapy medicinal products, where often there is a large upfront cost if the therapy is delivered in a single dose, with benefits stretching far into the future. They also point out that there is a minority of national HTA bodies (eg, in Belgium, the Netherlands, and Poland) that allow benefits to be discounted at a lower rate than costs. Also, in the case of prevention programs, which also typically have a high upfront cost, NICE in England and Wales suggests that analysts explore the implications of the discount rate for the estimates of benefits and hence the cost-effectiveness of the program.⁴⁰ Another issue relating to gene therapy is that individuals may receive additional utility in anticipation if they consider that their disease has been cured. The same argument has been made in the context of vaccination programs; namely, if individuals consider that the vaccine offers them protection from the disease, the benefit is received immediately, not at some point in the future.⁴¹

At this point there is not a strong enough case for departing from the general methodological principle of discounting costs and benefits at the same rate. Nevertheless, considering the aforementioned arguments, we recommend that the analyst explore the impact of using different discount rates for costs and benefits. In general, choosing a lower discount rate will be more favorable to gene therapies if a major proportion of the cost occurs in the first year, because the benefits are spread over a long period of time.

Dealing With Uncertainty

Uncertainty concerning the long-term effects of gene therapy has already been mentioned several times in this article. The standard analytic approach in economic evaluation for dealing with parameter uncertainty would be to use a model to extrapolate long-term costs and benefits using the best information possible and then to conduct a probabilistic sensitivity analysis. This would then form the basis for a value of information analysis to help determine what future investments in data collection should be made to reduce the decision uncertainty. There may also be structural uncertainty in designing any economic model. For example, should the model include a possibility of adverse events, the nature of which is completely unknown?

Nevertheless, in the case of gene therapy it is likely that the probabilistic sensitivity analysis would generate a wide confidence/credibility interval around the incremental cost-effectiveness ratio. Also, it is fairly clear that the main unknown is the long-term effectiveness of gene therapy and that the other major parameter in the economic evaluation is the incremental cost of gene therapy as compared with the current standard of care. Because most of the cost of gene therapy would be incurred upfront, it is largely known already.

This suggests that the capability of analysis to help deal with the uncertainty is limited. From a decision-making perspective, the most effective way of dealing with the uncertainty would be to devise a performance-based risk-sharing arrangement linking payment with the accumulated knowledge about the effectiveness of the therapy. The contribution of value of information analysis would be to help determine the main features of that arrangement.⁴²

The issues in developing these arrangements depend on the nature of the healthcare system, whether public or private, single-payer or multipayer. Karlsberg Schaffer et al⁴³ report some reluctance on the part of payers to assume too much financial risk, or to participate in payment arrangements that add a lot of complexity to already complicated processes for coverage and reimbursement. Although various insurance systems are structured in a way that introduce complexity, most notably in the United States, the most obvious way to solve for the unknown elements is to pay for the therapy over a set period of time rather than entirely upfront. By paying at a level commensurate with results, which might be structured as partial payment for less than full efficacy or elimination of future payments under certain conditions, it is possible to address concerns by payers that beneficiaries will not receive the full value of the therapy.

Apart from the reluctance of payers to embark on these arrangements, they pose a range of methodological and practical challenges, in study design, involvement of the relevant parties, and data collection and monitoring.⁴⁴ In multipayer systems like that in the United States, there is the additional complication that individuals may change insurance plans. Despite these challenges, the advent of gene therapy will likely give an increased impetus to solving them.

It is also important to agree on what a “fair” price is for the baseline case in which the gene therapy fully delivers on its promises. Economic evaluation, conducted along the lines specified earlier, can make an important contribution to price determination. It also raises the issue of how many years of cost savings should be factored into the price. The challenge of undertaking these assessments has fallen to different entities in various countries, and it is undeniable that even in countries like the United States, where basing reimbursement decisions on metrics such as QALYs has proven challenging and controversial, payers

Table 1. Checklist for assessing gene therapies.

Item	Yes	No	Notes
Clinical effectiveness			
Surrogate endpoint used	<input type="checkbox"/>	<input type="checkbox"/>	Validation given?
Rare disease	<input type="checkbox"/>	<input type="checkbox"/>	Prevalence _____
Serious condition	<input type="checkbox"/>	<input type="checkbox"/>	
Single-arm trial	<input type="checkbox"/>	<input type="checkbox"/>	Matched historical cohort used?
Pediatric population	<input type="checkbox"/>	<input type="checkbox"/>	Age range _____
Reporting of adverse consequences and risks	<input type="checkbox"/>	<input type="checkbox"/>	
Size of clinical trial	_____ number of patients		
Length of clinical trial	_____ duration in months		
Extrapolation to long-term outcomes	_____ duration in months		
	Yes	No	Quantification
Elements of value			
Severe disease	<input type="checkbox"/>	<input type="checkbox"/>	
Value to caregivers	<input type="checkbox"/>	<input type="checkbox"/>	
Insurance value	<input type="checkbox"/>	<input type="checkbox"/>	
Scientific spillovers	<input type="checkbox"/>	<input type="checkbox"/>	
Lack of alternatives	<input type="checkbox"/>	<input type="checkbox"/>	
Substantial improvement in life expectancy	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Notes
Other considerations			
Discounting			
Different discount rates explored	<input type="checkbox"/>	<input type="checkbox"/>	
Uncertainty			
Alternative payment models explored	<input type="checkbox"/>	<input type="checkbox"/>	

and others involved in the reimbursement decisions are paying closer attention to economic evaluations.

It should also be noted that there are other considerations that play into the question of a fair price: comparison to other treatments with similar characteristics, the size of the addressable population, the margins to the manufacturer, and so on. When there is no existing therapy for the condition in which the gene therapy is indicated, decision makers will be concerned about affordability as well as value for money.⁴³ Although we are recommending performance-based risk-sharing arrangements primarily as a way of dealing with uncertainty, these arrangements may also have the effect of spreading payments over time, which will help address affordability concerns.

Not all gene therapies are for conditions for which there are no alternative therapies. In some cases, gene therapy may be a replacement for treatments that are already very expensive, such as prophylaxis for hemophilia A in patients with inhibitors.⁴⁵ In such cases, gene therapy could potentially command a very high price. Nevertheless, when there are multiple alternative treatments for a given therapy, whether 2 or more gene therapies or various treatment types, the latter of which we are likely to see with hemophilia, for example, market competitive forces will also be an important factor.

Finally, it should be noted that those making policy determinations frequently question initial data, because the settings are generally ideal and most conducive to demonstrating positive results, as opposed to the environment of a busy clinician, who may not precisely be following the recommendations in clinical guidelines. For that reason, as well as the fact that many gene therapies coming to market have been tested on relatively small numbers of patients in ideal conditions, one can argue that innovative payment models are most important when a new therapy is first released and may be less of a requirement once real-world evidence has accumulated that creates greater agreement about the likely impact of treatment.

A Proposed Checklist for Assessing Gene Therapy

One approach for dealing with the additional considerations outlined earlier would be to produce a combined estimate of the value added by gene therapy. Nevertheless, as mentioned earlier, this approach is unlikely to be successful, because of the uncertainties in the measurement of many of the elements of value and in the ways of combining them in a single estimate. Rather, a more helpful approach would be to identify the main considerations in the assessment of gene therapy in a way that would assist decision makers in their deliberative decision-making processes.

The Second Panel on Cost-Effectiveness in Health and Medicine advanced the idea of an “impact inventory” to describe consequences of interventions both inside and outside of the formal healthcare sector, and to aid analysts in providing a complete and transparent account of the reference case.^{4,46} As Sanders et al⁴⁶ note, “if the results in the societal reference case differ substantially from those in the health care sector reference case, all identified effects should ideally be quantified, valued if possible, and reported in the results section.” Completing an impact inventory may be particularly important for gene therapies, given that such therapies can have important nonhealth consequences (eg, effects on family caregivers, education costs, and economic productivity).

In the spirit of the Second Panel’s impact inventory, it may also be useful to develop and apply a separate checklist for economic evaluations of gene therapies to clarify for audiences whether and to what extent other key elements affecting gene therapies have been identified and considered in analyses. Table 1 presents a sample checklist. The first section itemizes characteristics of gene therapy related to clinical effectiveness assessments, including whether the therapies are in areas of high unmet need or life-shortening conditions; whether surrogate endpoints have been

used; the sample size and duration of pivotal clinical trials used to approve the drugs; whether trials were single-arm, uncontrolled studies; whether trials included children and/or adults; whether studies were conducted in highly specialized centers; and to what extent trial results can be transferred and generalized to other settings.

The second section relates to the valuation of benefits for gene therapies, highlighting whether the study incorporated various novel elements of value. As noted, such elements may have heightened relevance for gene therapies. The checklist contains items, for example, to convey whether the economic evaluation considered and separately valued the therapy on the basis of severity of disease (ie, whether a gene therapy that improves the health of individuals in severe states is given a higher value) as well as caregiver burden, insurance value, scientific spillovers, and real option value.

The third section relates to any additional considerations, which, on the basis of the earlier discussion, would be the attention paid to the impact of discounting and the handling of uncertainty. As noted earlier, taken individually, none of the various elements in the checklist is exclusive to gene therapy; rather it is the *confluence* of these various characteristics that leads to specific methodological challenges and possibly the need for a different approach to economic evaluation. The checklist can serve as an organizing device, signaling to readers of economic evaluations the extent to which various factors were identified and considered formally in analyses.

Conclusions

Gene therapies do have a number of particular characteristics that suggest that the approach to economic evaluation should be modified. Nevertheless, in our view, these modifications do not imply the need for a new reference case. Rather, they suggest that particular aspects of the evaluation need further attention. We propose an additional checklist that can be used by analysts to determine which aspects of the evaluation should be considered further. Finally, there are some characteristics of gene therapy, such as the uncertainties about long-term benefits, that are not easily dealt with by developments in methods. For these aspects we also need innovations in payment systems to accompany any developments in methods.

Acknowledgments

We are grateful to AveXis Inc for financial support to the Forum for Gene Therapy Health Economics Group for research into the evaluation of gene therapies and to Madison Silver for help with the production of Table 1.

REFERENCES

- Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. *Cost-Effectiveness in Health and Medicine*. New York, NY: Oxford University Press; 1996.
- National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal*. London: National Institute for Health and Care Excellence; 2013.
- Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative Reference Case for economic evaluation: an aid to thought. *Value Health*. 2016;19(8):921–928.
- Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, eds. *Cost-Effectiveness in Health and Medicine*. 2nd ed. New York, NY: Oxford University Press; 2017.
- Tarricone R, Callea G, Ogerevic M, Rupel VP. Improving the methods for the economic evaluation of medical devices. *Health Econ*. 2017;26(suppl 1):70–92.
- Jena AB, Lakdawalla D. Value frameworks for rare diseases: should they be different? *Health Aff*. 2017. <https://doi.org/10.1377/hblog20170412.o59563>.
- Hepple R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. *Health Technol Assess*. 2017;21(7):1–204.
- Marsden G, Towse A, Pearson SD, et al. *Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. Report from the 2016 ICER Membership Policy Summit*. Boston, MA: Institute for Clinical and Economic Review; 2017.
- Jönsson B, Hampson G, Michaels J, et al. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. *Eur J Health Econ*. 2019;20(3):427–438.
- Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. *Am J Manag Care Spec Pharm*. 2019;1–7.
- Accelerated approval. Food and Drug Administration. <https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm>. Accessed January 2, 2019.
- European Medicines Agency. Adaptive pathways: key learnings and next steps. EMA/484516/2016. <https://www.ema.europa.eu/en/news/adaptive-pathways-key-learnings-next-steps>. Accessed January 2, 2019.
- European Medicines Agency. Enhanced early dialogue to facilitate accelerated assessment of PRiority Medicines (PRIME). EMA/CHMP/57760/2015. <https://www.ema.europa.eu/.../enhanced-early-dialogue-facilitate-accelerated-assessment-priority-medicines>. Accessed January 2, 2019.
- Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate endpoint and subsequent overall survival. *JAMA Intern Med*. 2015;175(12):1992–1994.
- Hanna E, Rémuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: current and future perspectives. *J Mark Access Health Policy*. 2016;4. <https://doi.org/10.3402/jmahp.v4.31036>.
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017;130(16):1800–1808.
- Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. *J Med Econ*. 2018;21(12):1238–1245.
- Berger ML, Martin BC, Husereau D, et al. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force Report. *Value Health*. 2014;17(2):143–156.
- Ciani O, Buyse M, Drummond MF, Rasi G, Saad E, Tatlor RS. Time to review the role of surrogate end points in health policy: state of the art and way forward. *Value Health*. 2017;20(3):487–495.
- Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumours: systematic review of statistical methods, results and implications for policy makers. *Int J Technol Assess Health Care*. 2014;30(3):312–324.
- Garrison LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements—good practices for design, implementation and evaluation. *Value Health*. 2013;16(5):703–719.
- International Society for Pharmacoeconomics and Outcomes Research. *Pharmacoeconomic guidelines around the world*. Sweden. 2019. <https://tools.ispor.org/peguidelines>. Accessed January 2, 2019.
- Garrison L, Neumann P, Willke R, et al. A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR Special Task Force Report [7]. *Value Health*. 2018;21(2):161–165.
- Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danson PM. Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force Report [3]. *Value Health*. 2018;21(2):131–139.
- George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision-making. *Pharmacoeconomics*. 2001;19(11):1103–1109.
- Shah KK. Severity of illness and priority setting in health care. *Health Policy*. 2009;93(2–3):77–84.
- National Institute for Health and Care Excellence. *Appraising Life-Extending, End of Life Treatments*. London: National Institute for Health and Care Excellence; 2009.
- Rowen D, Brazier J, Mukuria C, et al. Eliciting societal preferences for weighting QALYs for burden of illness and end of life. *Med Decis Making*. 2016;36(2):210–222.
- Taylor MJ, Chilton S, Ronaldson S, Metcalf H, Nielsen JS. Comparing increments in utility of health: an individual-based approach. *Value Health*. 2017;20(2):224–229.
- Weatherly H, Faria R, van den Berg B. Valuing informal care for caregiving. In: Culyer AJ, ed. *Elsevier Online Encyclopaedia of Health Economics*. Amsterdam, the Netherlands: Elsevier; 2014.
- van den Berg B, Fiebig DG, Hall J. Well-being losses due to care-giving. *J Health Econ*. 2014;35:123–131.

32. Lin PJ, D'Cruz B, Leech AA, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer's disease interventions. *Pharmacoeconomics*. 2019;37(4):597–608.
33. Blume-Kohout M. *Drug development and public research funding: evidence of lagged effect*. Santa Monica, CA: Working Paper. Rand Corp; 2009.
34. Phelps C, Lakdawalla D, Basu A, Drummond MF, Towse A, Danzon P. Approaches to aggregation and decision making—health economics approach: an ISPOR Special Task Force Report [5]. *Value Health*. 2018;21(2):146–154.
35. Sullivan SD, Yeung K, Vogeler C, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. *J Manag Care Spec Pharm*. 2015;21(4):269–275.
36. SMC modifiers used in appraising new medicines. Scottish Medicines Consortium. www.scotichmedicines.org.uk. Accessed December 12, 2018.
37. Persson U. *Value based pricing in Sweden: lessons for design*. OHE Seminar Briefing No. 12. London: Office of Health Economics; 2012.
38. National Institute for Health and Care Excellence. NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE's technology appraisal and highly specialised technologies programmes. <https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/board-paper-TA-HST-consultation-mar-17-HST-only.pdf>. Accessed January 31, 2019.
39. Drummond MF, Sculpher MJ, Claxton K, et al. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford, UK: Oxford University Press; 2015.
40. National Institute for Health and Care Excellence. *Methods for the Development of NICE Public Health Guidance*. 3rd ed. London: National Institute for Health and Care Excellence; 2012.
41. Drummond MF, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? *Vaccines*. 2007;25(32):5945–5957.
42. Claxton K, Palmer S, Longworth L, et al. A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions. *Value Health*. 2016;19(6):885–891.
43. Karlsberg Schaffer S, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A. Paying for cures: perspectives on solutions to the “affordability issue”. *Value Health*. 2018;21(3):276–278.
44. Drummond MF. When do performance-based risk-sharing arrangements make sense? *Eur J Health Econ*. 2015;16(6):569–571.
45. Doshi BS, Arruda VR. Gene therapy for haemophilia: What does the future hold? *Ther Adv Hematol*. 2018;9(9):273–293.
46. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *JAMA*. 2016;316(10):1093–1103.